NAA Services for Anti-Calcium and Integrin Binding 1 (CIB1) Protein
The scientific group for NAA (natural autoantibodies) study in Creative Biolabs consists of highly experienced leading experts that focused on disease diagnosis and therapies. With years of experience and high-end technologies in NAA research, we have successfully developed a series of innovative and diversified NAA platforms to provide fast and convenient services for our worldwide customers. CIB1 regulates platelet aggregation in hemostasis. A full range of anti-calcium and integrin binding 1 (CIB1) protein marker services for diseases diagnosis and therapeutic monitoring are available. We have confidence in our professional team to help you get a milestone development in your NAA project.
Background of Anti-Calcium and Integrin Binding 1 (CIB1) Protein
Calcium-binding proteins play a role in the regulation of numerous cellular processes, such as cell differentiation, cell division, cell proliferation, cell migration, thrombosis, angiogenesis, cardiac hypertrophy, and apoptosis. As a calcium-binding protein, calcium and integrin-binding protein 1 (CIB1) is a 22 kD, ubiquitously expressed protein that was first identified as an intracellular binding partner of a platelet-specific-integrin cytoplasmic tail. CIB1 is an EF-hand calcium binding protein, displaying a broad functional versatility in a number of cellular processes. This protein may be involved in cell survival and proliferation and is associated with several disease states. It coacts with many other proteins, including soluble and transmembrane proteins, by interacting with membrane-proximal domains, including the platelet integrin alpha-IIb-beta-3, B-cell lymphoma 2, caspase 2S, DNA protein kinase catalytic subunit protein kinase D. Interaction of CIB1 with its various binding partners provides valuable insight into potential mechanisms by which CIB1 may regulate diverse cellular processes ranging from adhesion, migration, and Ca2+ signaling to cell survival and proliferation.
Fig.1 Scheme of mechanism on regulation of Aβ production by CIB1. (Chiu, et al., 2020)
The Role of Anti-CIB1 Antibody in Pancreatic Cancer
Pancreatic cancer (PC) is caused by the abnormal and uncontrolled growth of cells in the pancreas, which is the third-leading cause of death from cancer in the United States. Despite the progress in diagnostic modalities and operative procedures, the prognosis for PC remains poor. Early-stage PC is asymptomatic and there is no sensitive diagnostic modality for its early detection. Autoantibodies to cancer antigens are candidates as possible biomarkers. CIB1 is up-regulated in a wide range of human cancers, and the high serum CIB1 levels are associated with PC. Increasing evidence indicates that the up-regulation may be a consequence of the common hyperactivation of the Ras-ERK pathway, and CIB1 may be an important mediator of Ras-induced oncogenesis. Anti-CIB1 antibody is significant and involved in enhancing cell survival, proliferation, and tumor angiogenesis. Therefore, CIB1 could be clinically used as a biomarker to detect PC.
What We Can Do About NAA?
NAA is a key component of immune surveillance function. Aided by our fully-trained technical support team, we now provide both standard and customized NAA services from NAA detection, NAA profiling, to NAA epitope mapping. A wide spectrum of NAA products is available for your choice. Our one-stop service can cover every step of your project.
Creative Biolabs offers our clients with the largest and diversiform portfolio of NAA products and services. Our proven and optimized platforms can help you quickly get satisfactory results without repeated trials. We also provide custom services based on the requirements of the clients in order to meet the specific demand. We’re committed to being your best companion to facilitate and maximize the success of your projects. Please contact us for more details or a detailed quote.
References:
- Chiu, Y. W.; et al. Identification of calcium and integrin‐binding protein 1 as a novel regulator of production of amyloid β peptide using CRISPR/Cas9‐based screening system. The FASEB Journal. 2020, 34(6): 7661-7674.
- Tina, M.; Leisner. CIB1: a small protein with big ambitions. The FASEB Journal. 2016, 30: 1-5.
Related Services:
- NAA Services for Anti-Coactosin-Like Protein (CLP)
- NAA Services for Anti-Mesothelin Antibody
- NAA Services for Anti-Ezrin
- NAA Services for Anti-ENOA1, 2 Antibody